The majority of known PAH risk genes rank in the top 5% of PC2 among 16,744 genes queried, and the new genes—FBLN2 and PDGFD—rank within the top 1.8%, providing support for their candidacy as PAH risk genes. This evidence concerns the gene PDGFD and pulmonary arterial hypertension.